Stokes Healthcare Inc., dba Epicur Pharma, Mt. Laurel, NJ

Is Stokes Healthcare Inc., dba Epicur Pharma registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Stokes Healthcare Inc., dba Epicur Pharma in Mt. Laurel, NJ, first registered Jan 30, 2018 and most recently registered Oct 14, 2026.

Does Stokes Healthcare Inc., dba Epicur Pharma hold a New Jersey pharmacy license?

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The California State Board of Pharmacy also lists nonresident license NSF 134 for Epicur Pharma, Mt Laurel, NJ, status Active, as of Nov 6, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054017688 for STOKES HEALTHCARE INC, MT LAUREL, NJ, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000903 for STOKES HEALTHCARE INC. (dba EPICUR PHARMA), MOUNT LAUREL, NJ, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0000067 for Epicur Pharma, MOUNT LAUREL, NJ, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301009513 for Stokes Healthcare, Inc., Mount Laurel, NJ, status Active and license 5301012201 for Stokes Healthcare Inc, Mount Laurel, NJ, status Active, as of Nov 10, 2026.

Has Stokes Healthcare Inc., dba Epicur Pharma had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Apr 2, 2024) and 1 untitled letter (Apr 27, 2022) for Stokes Healthcare Inc., dba Epicur Pharma. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for two years subject to the terms and conditions in the decision” dated Dec 10, 2025, case AC 7914 on nonresident license NSF 134. The Illinois Department of Financial and Professional Regulation’s license dataset also lists 2 actions: “Fine” dated Jan 11, 2019, case 2017010800 on nonresident license 054017688 and “Reprimand” dated Jan 11, 2019, case 2017010800 on nonresident license 054017688. The Virginia Department of Health Professions’ list of Board of Pharmacy case decisions from the last 90 days also lists 3 actions: “Probation” dated Oct 7, 2026 on nonresident license 0236000047, “Reinstatement Granted” dated Oct 7, 2026 on nonresident license 0236000047 and “Terms Imposed-Other” dated Oct 7, 2026 on nonresident license 0236000047.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Stokes Healthcare Inc., dba Epicur Pharma; Stokes Healthcare Inc.; Epicur Pharma
Location
Mt. Laurel, NJ
Type as FDA labels it
503B
FDA 503B list
Listed as Stokes Healthcare Inc., dba Epicur Pharma
Form 483s on FDA’s actions page
3
Warning letters on FDA’s actions page
1
Latest action on that page
May 23, 2025
FDA Data Dashboard inspections
4 inspections: 2 OAI, 2 VAI; 5 published Form 483s
Form 483 text on this page
2 Form 483s, 9 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Stokes Healthcare Inc., (dba Epicur Pharma), a 503B facility, with 5 dated actions.

Document
May 23, 2025Form 483483 issued 05/23/2025fda.gov
Apr 2, 2024Warning letterWarning Letter (04/02/2024)FDA copy (archived)
Oct 25, 2023Form 483483 Issued 10/25/2023FDA copy (archived)
Apr 27, 2022Untitled letterUntitled Letter 4/27/2022FDA copy (archived)
Oct 9, 2020Form 483483 Issued 10/09/2020FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Stokes Healthcare Inc., Mount Laurel, NJ (FEI number 3002815949), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 23, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30028159491267068
Oct 25, 2023Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30028159491221039
Oct 9, 2020Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30028159491131162
Feb 12, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3002815949957841

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 9 numbered observations in all, across 2 inspections ending Oct 9, 2020 to May 23, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 13, 2025 to May 23, 2025: 5 observations

Firm on the cover
Stokes Healthcare Inc. dba Epicur Pharma, 8000 Commerce Pkwy Ste 600, Mount Laurel, NJ 08054-2211
FEI number
3002815949
Establishment type on the cover
Producer of Sterile and Non -Sterile Drug Products
FDA district office on the cover
10 Waterview Blvd, 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

This is a repeat observation.

Specifically,

A. Your firm released several batches of Tacrolimus AQ Ophthalmic Suspension (without labeling them for veterinary use) and other veterinary products intended to be sterile, despite the detection of microbial growth during personnel monitoring (PM) and environmental monitoring (EM) within the ISO 5 production area since October 2023. Your firm has identified positive microbial growth during the EM/PM activities associated with the production of Tacrolimus AQ Ophthalmic Suspension (without labeling them for veterinary use), described as follows:

• MIR-010-2023: Tacrolimus AQ 0.02% Ophthalmic Suspension, Lot# R230600 -2 CFUs of Hansfordia sinuosae (a mold) were identified on the operator's right gloved hand. Date Occurred: 10/6/2023.

• MIR-005-2024: Tacrolimus AQ 0.03% Ophthalmic Suspension, Lot# R240103 -1 CFU of Streptomyces tendae/tritolerans was identified on the left wall within the ISO 5 aseptic processing area. Date Occurred: 2/27/2024. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

This is a repeat observation.

Specifically,

A. The sporicidal agent used to clean the ISO 5 aseptic area did not meet the contact time specified in the cleaning SOP. According to SOP SC-SAN-1010 Cleaning and Maintenance of the Aseptic Manufacturing Area, Revision 2.00, Effective Date: 7/29/2024 <Redacted B4> surface contact time has been established of <Redacted B4> however, camera footage dated 5/12/2025 shows that during the cleaning of the ISO 5 aseptic processing area immediately following the production of Tacrolimus AQ 0.5% (10 mL), Lot <Redacted B4> in Room 706, the operator applied <Redacted B4> at 10:16:59 and wiped it with a mop pre-saturated with <Redacted B4> at 10:21 :41 -resulting in a contact time of less than 5 minutes.

B. The camera footage dated 5/12/2025 shows that the operator did not thoroughly disinfect racks containing wells used to hold caps and tips inside the ISO 5 aseptic processing area prior to use during the production of Tacrolimus AQ 0.5% (10 mL), Lot# <Redacted B4>.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

This is a repeat observation.

Specifically,

The process validation for the Tacrolimus eye drops has not established critical control parameters. <Redacted B4>. During the aseptic filling of Tacrolimus eye drops, <Redacted B4> stir bar inside <Redacted B4> vessel <Redacted B4> stirs the bulk suspension product to maintain uniformity. However, the frrm has not established an acceptable operating range for the stir bar speed. For example, the stir bar speed settings for two different batches of Tacrolimus AQ 1 % Ophthalmic Suspension (Lot# 250197 and Lot# 250227) were <Redacted B4> and <Redacted B4> respectively without an established acceptable range. Since 2024, your frrm has reported 19 out-of-specification (OOS) batches of Tacrolimus eye drops. Of those, 9 batches had confrrmed OOS results and were rejected, but no definitive root causes have been identified during the manufacturing investigation. ...

Read the full 483 (PDF on fda.gov)

Observation 4

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically,

Your stability study failed to test for impurities of Tacrolimus Ophthalmic Suspension including :(6r(4) I individual unspecified impurities and total impurities as specified in the finished product specifications. For example, your firm failed to test for any of these impurities during the K6) (4) !stability study for Tacrolimus AQ 0.02% Ophthalmic Suspension, Lot# R230428 8/22/2023 and th [(6) (4) !stability study for Tacrolimus AQ 0.02% Ophthalmic Suspension, Lot# R230428, initiated on 8/22/2023. Impurities are tested at the time of product release; however, there is no assurance that impurity levels will remain within specification through the product's expiration date. Your firm manufactures approximately LJbatches of Tacrolimus Ophthalmic Suspension pe l(6) (4) lin Room 706.

Observation 5

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that conform to appropriate standards of identity, strength, quality and purity.

This is a repeat observation.

Specifically,

You firm has established an impurity specification for Tacrolimus AQ Ophthalmic Suspension; however, the method for impurity testing -Draft Test Method: Assay of Impurities in Tacrolimus AQ Ophthalmic Suspension by UPLC -has not yet been validated.

Inspection Sep 24, 2020 to Oct 9, 2020: 4 observations

Firm on the cover
Stokes Healthcare Inc. dba Epicur Pharma, 8000 Commerce Pkwy Ste 600, Mount Laurel, NJ 08054-2211
FEI number
3002815949
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Deviations from written production and process control procedures are not justified.

Specifically, after the <Redacted B4> were dropped or knocked to the floor following visual inspection. There was no investigation or justification as to why those units were not incubated for the balance of the <Redacted B4> and then inspected for _ turbidity/microbial growth. This media fill, <Redacted B4> , was performed in 6/2020. It was the <Redacted B4> used to validate aseptic processing in cleanroom C704, using your new ophthalmic bottle filling line.

Observation 2

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

Specifically, your firm lacks process control validation data to support the filling of ophthalmic drug products into 8ml and 4ml plastic bottles. Your validation data from 15ml bottles does not directly <Redacted B4>, which operate at <Redacted B4> . Data is missing on line speed conelation to downtime, the number of interventions in the ISO 5 area, and your firm's ability to maintain aseptic conditions throughout the manufacturing process.

on line speed conelation to downtime, the number of interventions in the ISO 5 area, and your film's ability to maintain aseptic conditions throughout the manufacturing process.

Observation 3

Procedures describing the handling of all written and oral complaints regarding a drug product are not established and followed.

Specifically, product complaints received between 3/10/2020 and 9/23/2020 were not entered into your Client Notice of Event Report and evaluated for product quality issues. At least seven (7) examples (complaints 20-007 to 20-0013) were noted.

Observation 4

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, your firm has not established bulk hold times in your master batch records or written procedures. The existing practice of <Redacted B4> ophthalmic liquids and injectable drug product <Redacted B4> does not establish a formal process control parameter. This deficiency could result in fwther processing and/or the release of a drug product which was not processed within validated parameters.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NSF 134Nonresident Outsourcing FacilityEpicur PharmaMt Laurel, NJActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054017688LICENSED PHARMACYSTOKES HEALTHCARE INCMT LAUREL, NJACTIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0000903NONRESIDENT PHARMACYSTOKES HEALTHCARE INC. (dba EPICUR PHARMA)MOUNT LAUREL, NJACTIVE (CURRENT)

Virginia Board of Pharmacy, board actions read Nov 15, 2026 (Virginia).

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0000067Outsourcing Facility-DistributorEpicur PharmaMOUNT LAUREL, NJActive

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301009513PharmacyStokes Healthcare, Inc.Mount Laurel, NJActive
5301012201PharmacyStokes Healthcare IncMount Laurel, NJActive

FDA’s 503B list

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.